Bayer seeks to purchase Monsanto, the merger would create the world’s largest supplier of seeds and chemicals.
Reports revealed their corporate labs conducts research projects on the active ingredient in marijuana, namely THC (tetrahydrocannabinol), to genetically manipulate the plant.
Excerpts from Ellen Brown’s report: The War on Weed Part II: Monsanto, Bayer, and the Push for Corporate Cannabis Posted on July 7, 2016 by Ellen Brown
Powerful corporate interests no doubt had a hand in keeping cannabis off the market. The question now is why they have suddenly gotten on the bandwagon for its legalization. According to an April 2014 article in The Washington Times, the big money behind the recent push for legalization has come, not from a grassroots movement, but from a few very wealthy individuals with links to Big Ag and Big Pharma.
Leading the charge is George Soros, a major shareholder in Monsanto, the world’s largest seed company and producer of genetically modified seeds. Monsanto is the biotech giant that brought you Agent Orange, DDT, PCBs, dioxin-based pesticides, aspartame, rBGH (genetically engineered bovine growth hormone), RoundUp (glyphosate) herbicides, and RoundUp Ready crops (seeds genetically engineered to withstand glyphosate).
Monsanto now appears to be developing genetically modified (GMO) forms of cannabis, with the intent of cornering the market with patented GMO seeds just as it did with GMO corn and GMO soybeans. For that, the plant would need to be legalized but still tightly enough controlled that it could be captured by big corporate interests.
Natural health writer Mike Adams warns:
[W]ith the cannabis industry predicted to generate over $13 billion by 2020, becoming one of the largest agricultural markets in the nation, there should be little doubt that companies like Monsanto are simply waiting for Uncle Sam to remove the herb from its current Schedule I classification before getting into the business.
The next stage in continuing this control is in the regulation, licensing and taxation of Cannabis cultivation and use through the only practical means available to the corporate system, which is through genetic engineering and patenting of the Cannabis genome.
Soros is a major player in Uruguay and was instrumental in getting the law passed. He sits on the board of the New York-based Drug Policy Alliance (DPA), the world’s most influential organization for cannabis legalization. The DPA is active not only in the US but in Uruguay and other Latin American countries. Engdahl writes:
Studies show that Monsanto without much fanfare conducts research projects on the active ingredient in marijuana, namely THC (tetrahydrocannabinol), in order to genetically manipulate the plant. David Watson of the Dutch company Hortapharm has since 1990 created the world’s largest collection of Cannabis seed varieties. In 1998, the British firm GW Pharmaceuticals signed an agreement with Hortapharm that gives GW Pharma the rights to use the Hortapharm cannabis for their research.
In 2003 the German Bayer AG then signed an agreement with GW Pharmaceuticals for joint research on a cannabis-based extract. In 2007, Bayer AG agreed to an exchange of technology with . . . Monsanto . . . . Thus Monsanto has discreet access to the work of the cannabis plant and its genetic modification. In 2009 GW Pharmaceuticals announced that it had succeeded in genetically altering a cannabis plant and patented a new breed of cannabis.
Monsanto could have even greater access to the Bayer/GW research soon. In March 2016, Monsanto approached the giant German chemical and pharmaceutical company Bayer AG with a joint venture proposal concerning its crop science unit. In May, Bayer then made an unsolicited takeover bid for Monsanto. On May 24th, the $62 billion bid was rejected as too low; but negotiations are continuing.
AUMA: Wolf in Sheep’s Clothing?
Suspicions like these are helping to fuel opposition to the Adult Use of Marijuana Act (AUMA), a 2016 initiative that would rewrite the medical marijuana laws in California. While AUMA purports to legalize marijuana for recreational use, the bill comes with so many restrictions that it actually makes acquisition more difficult and expensive than under existing law, and makes it a criminal offense for anyone under 21. Critics contend that the Act will simply throw access to this medicinal wonder plant into the waiting arms of the Monsanto/Bayer/petrochemical/pharmaceutical complex. They say AUMA is a covert attempt to preempt California’s Compassionate Use Act, Proposition 215, which was passed in 1996 by voter initiative.
Prop 215 did not legalize the sale of marijuana, but it did give ill or disabled people of any age the right to grow and share the plant and its derivatives on a not-for-profit basis. They could see a doctor of their choice, who could approve medical marijuana for a vast panoply of conditions; and they were assured of safe and affordable access to the plant at a nearby cooperative not-for-profit dispensary, or in their own backyards. As clarified by the 2008 Attorney General’s Guidelines, Prop 215 allowed reimbursement for the labor, costs and skill necessary to grow and distribute medical marijuana; and it allowed distribution through a “storefront dispensing collective.” However, the sale of marijuana for corporate profit remained illegal. Big Pharma and affiliates were thus blocked from entering the field.
At the end of 2015 (effective 2016), the California state legislature over-rode Prop 215 with MMRSA – the Medical Marijuana Regulation and Safety Act of 2015/16 – which effectively rewrites the Health Code pertaining to medical marijuana. Opponents contend that MMRSA is unconstitutional, since a voter initiative cannot be changed by legislative action unless it so provides. And that is why its backers need AUMA, a voter initiative that validates MMRSA in its fine print. In combination with stricter California Medical Association rules for enforcement, MMRSA effectively moves medical marijuana therapy from the wholistic plant to a pharmaceutical derivative, one that must follow an AUMA or American Pharmaceutical Association mode of delivery.
Read full report.
and the earlier June 23, 2016 report.